IBEX Technologies
5485 Pare Street
Montreal
Quebec
H4P 1P7
Canada
Tel: 514-344-4004
Fax: 514-344-8827
Website: http://www.ibex.ca/
About IBEX Technologies
IBEX Technologies is a Montreal based company that manufactures and markets reagents for biomedical use through its wholly owned subsidiary IBEX Pharmaceuticals Inc.
The company's product line comprises high purity enzymes for in-vitro diagnostics and research, as well ELISA kits for osteoarthritis research.
IBEX also provides custom production services to the major players in the in-vitro diagnostic market, including custom fermentation as well as filling and lyophilization for disposable diagnostic components.
The IBEX Pharmaceutical's Quality Management System is certified ISO 13485:2016
IBEX has been operational in Montreal since 1987.
74 articles about IBEX Technologies
-
IBEX Files Addendum to Management Proxy Circular for Sale of the Company at $1.45 Per Share
3/14/2024
IBEX Technologies Inc. announces that it has filed an addendum to its management proxy circular dated February 23, 2024 for the annual and special meeting of shareholders to be held in Montreal, Québec on April 3, 2024.
-
IBEX Technologies Signs Definitive Agreement for Sale of the Company for $1.45 Cash Per Share
2/12/2024
IBEX Technologies Inc. (“ IBEX ” or the “ Company ”) (TSX Venture: IBT) is pleased to announce that it has entered into a binding acquisition agreement dated February 9, 2024 (the “ Acquisition Agreement ”) and related agreements with 15720273 Canada Inc. (the “ Purchaser ”), a newly-incorporated, wholly-owned subsidiary of BBI Solutions OEM Limited (“ BBI ”), whereby BBI will acquire all of the issued and outstanding shares of IBEX at a price of $1.
-
IBEX Reports Results for the Year Ended July 31, 2023
11/9/2023
IBEX Technologies Inc. reported its financial results for the fiscal year ended July 31, 2023.
-
IBEX Technologies Announces Renewal of Normal Course Issuer Bid
7/17/2023
IBEX Technologies Inc. announced that the TSX Venture Exchange has conditionally approved the renewal of IBEX’s normal course issuer bid.
-
IBEX Reports Results for the Third Quarter and the Nine Months Ended April 30, 2023
6/7/2023
IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the third quarter and the nine months ended April 30, 2023.
-
IBEX Reports Results for the Second Quarter and the Six Months Ended January 31, 2023
3/20/2023
IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the second quarter and the six months ended January 31, 2023.
-
IBEX Reports Results for the First Quarter Ended October 31, 2022
12/15/2022
IBEX Technologies Inc. reported its financial results for the three months ended October 31, 2022.
-
IBEX Reports Results for the Year Ended July 31, 2022
11/10/2022
IBEX Technologies Inc. reported its financial results for the fiscal year ended July 31, 2022.
-
IBEX Reports Results for the Third Quarter and the Nine Months Ended April 30, 2022
6/10/2022
IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the nine months ended April 30, 2022.
-
IBEX Reports Results for the Second Quarter and the Six Months Ended January 31, 2022
3/17/2022
IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the six months ended January 31, 2022.
-
IBEX Announces Results of Annual Meeting
2/17/2022
IBEX Technologies Inc. is pleased to announce that all six nominees listed in its management proxy circular dated January 4, 2022 were re-elected as directors at the Company’s annual and special meeting held in Montreal.
-
IBEX Announces Stock Option Grant to Directors and Employees
12/23/2021
IBEX Technologies Inc. (TSX Venture: IBT), today announced that on December 22, 2021 the Company’s Board of Directors granted stock options representing a total of 450,000 common shares to its directors and an officer of the Company.
-
IBEX Reports Results for the First Quarter Ended October 31, 2021
12/15/2021
IBEX Technologies Inc. reported its financial results for the three months ended October 31, 2021.
-
IBEX Reports Results for the Year Ended July 31, 2021
11/11/2021
IBEX Technologies Inc. reported its financial results for the fiscal year ended July 31, 2021.
-
IBEX Reports Results for the Second Quarter and the Six Months Ended January 31, 2021
3/17/2021
IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the six months ended January 31, 2021.
-
IBEX to Livestream Annual Meeting on January 20
1/13/2021
IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) announces that the location of its annual meeting (the “Meeting”) to be held on Wednesday, January 20, 2021 has been changed to IBEX’s head office, 5485 Paré Street, Suite 100, Montreal, Québec H4P 1P7 and the time of the Meeting has been changed to 11 a.m.
-
IBEX Reports Results for the First Quarter Ended October 31, 2020
12/9/2020
IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the three months ended October 31, 2020.
-
IBEX Reports Results for the Year Ended July 31, 2020
11/5/2020
IBEX Technologies Inc. reported its financial results for the fiscal year ended July 31, 2020.
-
IBEX Reports Management Change - Oct 01, 2020
10/1/2020
IBEX Technologies Inc. is pleased to announce that Belinda Franco, CPA, CA has joined IBEX and will become Director of Finance and Chief Financial Officer.
-
IBEX Reports Management Change
8/27/2020
IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported that Richard Collin, Director of Finance, has advised IBEX that he will leave the Company effective September 3, 2020.